Viromed Medical AG Gains Approval for ViroCAP® med in Turkey

Viromed Medical AG, a leader in cold plasma technology, has secured approval for its ViroCAP® med device in Turkey. This approval allows the medical device, classified as MDR Class IIa, to be applied in medical procedures, specifically for treating open wounds and intraoperative use on the Turkish market.

CEO Uwe Perbandt highlighted the significance of this approval, noting its role in Viromed's international expansion. The approval precedes their anticipated timeline, marking a pivotal step in their strategic entry into the Turkish healthcare market.

Viromed has secured commitments for 7,000 units of ViroCAP® derma/med through 2028 in Turkey. The company is also pursuing approvals in other Asian markets, leveraging its EU MDR classification as a foundation.

Furthermore, Viromed achieved its first reimbursement deal with a health insurer in Lower Saxony, Germany. This contract focuses on preventing infections in patients with left ventricular assist devices.